Summit Therapeutics PLC SMMT
15.61
(0.77)
(4.70%)
as of 25 Sep
- Market cap
- $13.1B
- P/E
- 0.0×
Follow SMMT
Insider Buys
alert about insiders buying in the last 12 month
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Jan '19 | Dec '18 | Jan '18 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.60 | 0.00 | 0.00 |
P/S ratio |
— | — | — | 1,371.18 | 195.86 | 379.96 | 92.88 | 0.20 | 0.57 | 30.42 |
P/FCF ratio |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
— | — | — | 186.22 | (38.60) | (40.99) | (4.39) | (0.64) | (3.72) | (9.40) |
P/B ratio |
— | — | — | 7.63 | 4.25 | 4.11 | 0.67 | 0.41 | 0.52 | 13.98 |
Price to Tangible BV |
— | — | — | 7.74 | 5.00 | 4.96 | 0.82 | 0.58 | 0.95 | 0.00 |
EV/Sales |
— | — | — | 1,152.64 | 156.22 | 302.81 | (19.12) | (0.11) | 0.06 | 26.00 |
EV/EBITDA |
— | — | — | 0.00 | 0.00 | 0.00 | 0.42 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | — | — | (19.54) | (3.89) | (5.41) | 0.24 | 0.28 | (0.07) | (3.25) |
EV/FCF |
— | — | — | (19.17) | (3.87) | (5.35) | 0.23 | 0.28 | (0.07) | (3.19) |
Quick Ratio |
9.87 | 10.15 | 9.30 | 16.92 | 3.75 | 4.33 | 5.68 | 3.63 | 1.29 | 1.89 |
Current Ratio |
9.87 | 10.15 | 9.30 | 16.93 | 3.80 | 4.41 | 5.78 | 3.63 | 1.58 | 1.89 |
Net Debt/EBITDA |
0.65 | 1.83 | 0.14 | 2.21 | 0.86 | 1.30 | 2.45 | (3.45) | 0.83 | 1.60 |
Debt/Assets |
0.00% | 0.00% | 49.27% | 74.46% | 0.00% | 0.07% | 0.44% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 1.29 | 3.90 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.01 | 0.01 | 0.73 | 0.22 | 0.56 |
Operating CF/Net income |
0.30 | 0.64 | 0.12 | 0.53 | 0.82 | 0.91 | 0.71 | (3.56) | 0.73 | 2.06 |
Capex/Depreciation |
(4.50) | (1.56) | 0.49 | (0.25) | (0.12) | (0.21) | (0.21) | (0.11) | 0.00 | (1.95) |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 |
| (206.10%) | (94.90%) | (601.85%) | (75.05%) | (108.89%) | (66.57%) | (43.05%) | 38.47% | (630.66%) | (219.48%) | |
| (181.94%) | (69.32%) | (141.83%) | (20.26%) | (82.09%) | (53.03%) | (33.19%) | 12.80% | (35.72%) | (15.79%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | (468.69%) | (253.57%) | (111.17%) | 26.51% | 0.00% | 0.00% |
Return on Tangible Assets |
(166.51%) | (57.89%) | (362.77%) | (12.73%) | (122.41%) | (76.92%) | (43.88%) | 21.83% | (132.47%) | (40.16%) |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 3,944.59 | 4,907.02 | 8,375.48 | 7,067.64 | 168.66 | 300.10 | 226.71 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 7,375.74% | 4,718.19% | 6,194.65% | 5,357.87% | 91.08% | 233.53% | 113.97% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 3,793.33% | 1,305.20% | 2,236.28% | 1,518.03% | 28.69% | 79.55% | 47.20% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.01 | 0.00 | 0.11 | 0.13 | 0.16 | 0.21 | 0.32 | 0.32 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 1,694.75% | 707.79% | 205.35% | 113.73% | 11.03% | 0.00% | 6.32% |
Graham Net Nets |
— | — | — | 0.12 | 0.19 | 0.20 | 1.19 | 1.70 | 1.01 | (0.06) |
Graham Number |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 12.75 | 0.00 | 0.00 |
Earnings Yield |
— | — | — | (8.90%) | (35.69%) | (16.20%) | (57.94%) | 166.38% | (61.67%) | (8.87%) |
Free Cash Flow Yield |
— | — | — | (4.38%) | (20.62%) | (14.91%) | (88.61%) | (197.77%) | (154.07%) | (26.75%) |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.02 | 3.33 | 0.08 | 2.53 |
Operating CF per Share |
(0.43) | (0.20) | (0.12) | (0.22) | (0.55) | (0.69) | (0.63) | (2.07) | (0.10) | (1.46) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.01) | (0.01) | (0.01) | 0.00 | (0.05) |
Free Cash Flow per Share |
(0.43) | (0.20) | (0.12) | (0.22) | (0.55) | (0.70) | (0.64) | (2.08) | (0.10) | (1.51) |
Cash per Share |
0.95 | 0.57 | 0.30 | 3.35 | 0.55 | 0.96 | 1.94 | 2.08 | 0.14 | 2.00 |
Shareholders Equity per Share |
0.88 | 0.54 | 0.13 | 0.66 | 0.63 | 1.14 | 2.40 | 3.29 | (0.02) | 0.98 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.88 | 0.54 | 0.13 | 0.66 | 0.63 | 1.14 | 2.40 | 3.29 | (0.02) | 0.98 |
Free Cash Flow |
(323.59) | (142.24) | (76.66) | (42.21) | (72.89) | (48.53) | (21.10) | (35.71) | (19.08) | (19.74) |
Working Capital |
647.31 | 382.02 | 169.31 | 617.93 | 71.69 | 67.78 | 65.86 | 44.93 | 18.66 | 22.05 |
Capital Expenditures |
(0.66) | (0.14) | 0.10 | (0.62) | (0.31) | (0.42) | (0.34) | (0.17) | (0.62) | (0.62) |
Net Current Asset Value |
627.98 | 376.94 | 64.46 | 119.20 | 67.22 | 64.63 | 62.24 | 39.15 | (30.23) | (10.67) |
EV/EBIT |
— | — | — | 0.00 | 0.00 | 0.00 | 0.37 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.89 | 0.17 | 0.49 | 0.46 | 0.00 | 0.00 | 0.02 |
Net Profit Margin |
0.00% | 0.00% | 0.00% | (11,174.75%) | (4,897.84%) | (6,127.56%) | (3,920.19%) | 17.50% | (163.35%) | (28.05%) |
Price to Operating Income |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.48 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.14 | 0.35 | 0.97 | 2.77 | 3.54 | 2.76 | 3.16 | 1.85 | 0.28 | 0.30 |
Cash ROIC |
(23.60%) | (17.76%) | (21.15%) | (3.35%) | (47.26%) | (33.46%) | (14.86%) | (39.50%) | (84.09%) | (51.70%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.04 | 0.08 | 0.05 | 0.04 | 2.88 | 0.95 | 2.51 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
8.81 | 7.27 | 5.54 | 15.97 | 22.03 | 17.06 | 20.38 | 19.79 | 16.88 | 13.16 |
Average Payables |
12.46 | 3.65 | 1.51 | 2.36 | 5.26 | 5.31 | 8.12 | 9.02 | 8.95 | 6.38 |
Average Assets |
593.37 | 319.25 | 433.56 | 388.77 | 107.94 | 99.37 | 87.77 | 78.01 | 73.48 | 58.76 |
Average Common Equity |
523.80 | 233.22 | 102.17 | 104.97 | 81.37 | 79.16 | 67.65 | 25.96 | 4.16 | 4.23 |
Columns are period end dates